We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA Warns of Increased Costs If FDA Labeling Rule Is Finalized
GPhA Warns of Increased Costs If FDA Labeling Rule Is Finalized
In an effort to build opposition to the FDA’s proposed generic drug safety labeling rule, GPhA is warning that spending on generics will rise by $4 billion per year if the rule is finalized.